Skip to main content

Advertisement

Log in

Circulating vascular endothelial growth factor in the normo- and/or microalbuminuric patients with type 2 diabetes mellitus

  • Original Article
  • Published:
Acta Diabetologica Aims and scope Submit manuscript

Abstract

Relationship between serum vascular endothelial growth factor (VEGF) level and parameters of endothelial injury and/or dysfunction in patients with diabetes mellitus type 2 with or without microalbuminuria was investigated. Eighty-four diabetic patients were divided in two subgroups (42 each): normoalbuminuric (NAU) and microalbuminuric (MAU). Forty-two blood donors were in control group. Serum VEGF and plasma von Willebrand factor, soluble thrombomodulin, plasminogen activator inhibitor 1, thrombin-activatable fibrinolysis inhibitor (TAFI) and tissue plasminogen activator (t-PA) were measured using enzyme-linked immunosorbent assay in all subjects. VEGF was significantly higher in NAU compared to controls. The difference between MAU and controls was not statistically significant, but there was a trend toward significance. Only TAFI correlated with VEGF in MAU. An observed significant increase of serum VEGF level already in NAU suggests that serum VEGF could be a sensitive predictor of endothelial dysfunction in type 2 diabetes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Schrijvers BF, Flyvbjerg A, De Vriese AS (2004) The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int 65:2003–2017

    Article  CAS  PubMed  Google Scholar 

  2. Wolf G, Ziyadeh FN (2007) Cellular and molecular mechanisms of proteinuria in diabetic nephropathy. Nephron Physiol 106:26–31

    Article  Google Scholar 

  3. Khamaisi M, Schrijvers BF, De Vriese AS et al (2003) The emerging role of VEGF in diabetic kidney disease. Nephrol Dial Transplant 18:1427–1430

    Article  CAS  PubMed  Google Scholar 

  4. Flyvbjerg A (2000) Putative pathophysiological role of growth factors and cytokines in experimental diabetic kidney disease. Diabetologia 43:1205–1223

    Article  CAS  PubMed  Google Scholar 

  5. Chiarelli F, Spagnoli A, Basciani F et al (2000) Vascular endothelial growth factor (VEGF) in children, adolescents and young adults with type 1 diabetes mellitus: relation to glycaemic control and microvascular complications. Diabetes UK Diabet Med 17:650–656

    CAS  Google Scholar 

  6. Knöbl P, Schernthaner G, Schnack C et al (1993) Thrombogenic factors are related to urinary albumin excretion rate in type 1 (insulin-dependent) and type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36:1045–1050

    Article  PubMed  Google Scholar 

  7. Santilli F, Spagnoli A, Mohn A et al (2001) Increased vascular endothelial growth factor serum concentrations may help to identify patients with onset of type 1 diabetes during childhood at risk for developing persistent microalbuminuria. J Clin Endocrinol Metab 86:3871–3876

    Article  CAS  PubMed  Google Scholar 

  8. Hovind P, Tarnow L, Oestergaard PB et al (2000) Elevated vascular endothelial growth factor in type 1 diabetic patients with diabetic nephropathy. Kidney Int 57(Suppl 75):S56–S61

    Article  Google Scholar 

  9. Wasada T, Kawahara R, Katsumori K et al (1998) Plasma concentration of immunoreactive vascular endothelial growth factor and its relation to smoking. Metabolism 47:27–30

    Article  CAS  PubMed  Google Scholar 

  10. Blann AD, Belgore FM, McCollum CN et al (2002) Vascular endothelial growth factor (VEGF) and its receptor, Flt-1, in the plasma of patients with coronary or peripheral atherosclerosis, or type II diabetes. Clin Sci 102:187–194

    Article  CAS  PubMed  Google Scholar 

  11. Shimada K, Baba T, Neugebauer S et al (2002) Plasma vascular endothelial growth factor in Japanese Type 2 diabetic patients with and without nephropathy. J Diabetes Complications 16:386–390

    Article  CAS  PubMed  Google Scholar 

  12. Kim NH, Kim KB, Kim DL et al (2004) Plasma and urinary vascular endothelial growth factor and diabetic nephropathy in type 2 diabetes mellitus. Diabetes UK Diabet Med 21:545–551

    CAS  Google Scholar 

  13. Kim NH, Oh JH, Seo JA et al (2005) Vascular endothelial growth factor (VEGF) and soluble VEGF receptor FLT-1 in diabetic nephropathy. Kidney Int 67:167–177

    Article  CAS  PubMed  Google Scholar 

  14. Cha DR, Kang YS, Han SY et al (2004) Vascular endothelial growth factor is increased during early stage of diabetic nephropathy in type II diabetic rats. J Endocrinol 183:183–194

    Article  CAS  PubMed  Google Scholar 

  15. Heywood DM, Mansfield MW, Grant PJ (1996) Levels of von Willebrand factor, insulin resistance syndrome, and a common vWF gene polymorphism in non-insulin-dependent (type 2) diabetes mellitus. Diabet Med 13:720–725

    Article  CAS  PubMed  Google Scholar 

  16. Collier A, Rumley A, Rumley AG et al (1992) Free radical activity and hemostatic factors in NIDDM patients with and without microalbuminuria. Diabetes 41:909–913

    Article  CAS  PubMed  Google Scholar 

  17. Schmitz A, Ingerslev J (1990) Haemostatic measures in type 2 diabetic patients with microalbuminuria. Diabet Med 7:521–525

    Article  CAS  PubMed  Google Scholar 

  18. Gabat S, Keller C, Kempe HP et al (1996) Plasma thrombomodulin: a marker for microvascular complications in diabetes mellitus. Vasa 25:233–241

    CAS  PubMed  Google Scholar 

  19. Inukai T, Fujiwara Y, Tayama K et al (1996) Clinical significance of measurements of urinary and serum thrombomodulins in patients with non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 33:99–104

    Article  CAS  PubMed  Google Scholar 

  20. Nilsson TK, Hellsten G, Amiral J (1993) Plasma thrombomodulin concentrations in relation to cardiovascular risk factors in a population sample. Blood Coagul Fibrinolysis 4:455–458

    Article  CAS  PubMed  Google Scholar 

  21. Yano Y, Kitagawa N, Gabazza EC et al (2003) Increased plasma thrombin-activatable fibrinolysis inhibitor levels in normotensive type 2 diabetic patients with microalbuminuria. J Clin Endocrinol Metab 88:736–741

    Article  CAS  PubMed  Google Scholar 

  22. Gruden G, Cavallo-Perin P, Romagnoli R et al (1994) Prothrombin fragment 1 + 2 and antithrombin III-thrombin complex in microalbuminuric type 2 diabetic patients. Diabet Med 11:485–488

    Article  CAS  PubMed  Google Scholar 

  23. Leurs PB, Stolk RP, Hamulyak K et al (2002) Tissue factor pathway inhibitor and other endothelium-dependent hemostatic factors in elderly individuals with normal or impaired glucose tolerance and type 2 diabetes. Diabetes Care 25:1340–1345

    Article  CAS  PubMed  Google Scholar 

  24. Kario K, Matsuo T, Kobayashi H et al (1995) Activation of tissue factor-induced coagulation and endothelial cell dysfunction in non-insulin-dependent diabetic patients with microalbuminuria. Arterioscler Thromb Vasc Biol 15:1114–1120

    CAS  PubMed  Google Scholar 

  25. Miccoli R, Giampietro O, Penno G et al (1989) ‘Microalbuminuria’ in type I (insulin-dependent) diabetic patients with and without retinopathy. Acta Diabetol Lat 26(2):163–170

    Article  CAS  PubMed  Google Scholar 

  26. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (2003) Report. Diabetes Care 26(Suppl 1):S5–S20

  27. Tütüncü NB, Gürlek A, Gedik O (2001) Efficacy of ACE inhibitors and ATII receptor blockers in patients with microalbuminuria: a prospective study. Acta Diabetol 38(4):157–161

    Article  PubMed  Google Scholar 

  28. McLaren M, Elhadd TA, Greene SA et al (1999) Elevated plasma vascular endothelial cell growth factor and thrombomodulin in juvenile diabetic patients. Clin Apll Thromb Haemost 5:21–24

    Article  CAS  Google Scholar 

  29. Chaturvedi N, Fuller JH, Pokras F et al (2001) Circulating plasma vascular endothelial growth factor and microvascular complications of type 1 diabetes mellitus: the influence of ACE inhibition. Diabet Med 18:288–294

    Article  CAS  PubMed  Google Scholar 

  30. Sharp PS, Al-Mrayat M, Valabhji J et al (1998) Serum levels of vascular endothelial growth factor in diabetic subjects: the relationship with blood pressure. Diabetologica 41:984–985

    Article  CAS  Google Scholar 

  31. García de la Torre N, Rubio MA, Bordiú E et al (2008) Effects of weight loss after bariatric surgery for morbid obesity on vascular endothelial growth factor-A, adipocytokines, and insulin. J Clin Endocrinol Metab 93(11):4276–4281

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

The work was supported by grants VEGA 1/2309/05, 1/3381/06 and Comenius University grants 77/2007 and 421/2008. Hereby, we would like to express our thanks to Jozefína Petrovičová, MSc., PhD. from the Institute of Medical Informatics, Medical Faculty of Pavol Jozef Šafárik, University in Košice for her considerable help with the statistical evaluation of our results.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Peter Kubisz.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kubisz, P., Chudý, P., Staško, J. et al. Circulating vascular endothelial growth factor in the normo- and/or microalbuminuric patients with type 2 diabetes mellitus. Acta Diabetol 47, 119–124 (2010). https://doi.org/10.1007/s00592-009-0127-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00592-009-0127-2

Keywords

Navigation